Characterizing the role of TGFBR2 in ESCC could pave the way to a deeper understanding of the potential mechanisms underlying disease development as well as illuminate its potential as a biomarker for early diagnosis and personalized therapeutic agent for ESCC patients. The gene discussed is TGFBR2; the disease is esophageal squamous cell carcinoma.